ARTHUR MYRON FELDMAN
Medical Practice in Penn Wynne, PA
License number
Pennsylvania MD015294E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Penn Wynne, PA 19096
Personal information
See more information about ARTHUR MYRON FELDMAN at radaris.comName
Address
Phone
554 Hansell Rd, Wynnewood, PA 19096
100 West Ave APT W702, Jenkintown, PA 19046
100 West Ave STE 100, Jenkintown, PA 19046
1010 Laclair St, Pittsburgh, PA 15218
1342 Cardinal Dr, Pittsburgh, PA 15243
Professional information
See more information about ARTHUR MYRON FELDMAN at trustoria.com
Adenosine A1 And A3 Receptor Gene Sequence Variations For Predicting Disease Outcome And Treatment Outcome
Adenosine A1 And A3 Receptor Gene Sequence Variations For Predicting Disease Outcome And Treatment Outcome
US Patent:
2010004, Feb 25, 2010
Filed:
Nov 8, 2007
Appl. No.:
12/514031
Inventors:
Arthur M. Feldman - Wynnewood PA, US
Zhong Tang - Cherry Hill NJ, US
Zhong Tang - Cherry Hill NJ, US
Assignee:
THOMAS JEFFERSON UNIVERSITY - Philadelphia PA
International Classification:
C12Q 1/68, C07H 21/04, C07K 2/00, C07K 16/00, G06F 19/00
US Classification:
435 6, 536 2431, 530300, 5303871, 5303873, 702 19
Abstract:
The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene.
Compositions And Methods For The Treatment And Prevention Of Cardiovascular Diseases
Compositions And Methods For The Treatment And Prevention Of Cardiovascular Diseases
US Patent:
2010027, Oct 28, 2010
Filed:
Dec 12, 2008
Appl. No.:
12/747147
Inventors:
Arthur Feldman - Wynnewood PA, US
Tung Chan - Huntington Valley PA, US
Tung Chan - Huntington Valley PA, US
Assignee:
THOMAS JEFFERSON UNIVERSITY - PHILADELPHIA PA
International Classification:
A61K 39/395, A61K 38/14, A61K 31/7088, A61K 31/7084, A61K 31/7052, A61K 38/00, A61K 31/437, A61K 31/7076, A61K 31/538, A61K 31/502, A61P 9/04, A61P 9/00, A61P 9/10
US Classification:
4241301, 514 44 R, 514 209, 514 11, 514 44 A, 514303, 514 46, 5142305, 514248
Abstract:
The present invention is directed to a pharmaceutical composition, and methods of use thereof, comprising at least one agent which target multiple adenosine receptors (AR) simultaneously in a stoichiometric relationship (i.e. each AR receptor is targeted to an equal extent). Aspects of the present invention relate to pharmaceutical compositions, and uses thereof, comprising at least one agent which co-activates an A-adenosine receptor (A-AR) and an A-adenosine receptor (A-AR) or a combination of at least one agent which activates an A-AR and at least one agent which activates an A-AR, where both the A-AR and A-AR are activated in a stoichiometric relationship such that the level of biological activation of A-AR is approximately the same level of biological activation of A-AR. Other aspects of the present invention relates to methods for the therapeutic and prophylactic treatment of cardiac dysfunction in a subject having or at risk of having a cardiac dysfunction, for example, but not limited to, for the treatment of a subject with myocardial infarction, such as acute myocardial infarction, coronary ischemia or congestive heart failure and other cardiac dysfunctions.